The special AT-rich sequence-binding protein 2 (SATB2) is a well-established tumor suppressor in NSCLC, but its downstream epigenetic and metabolic regulatory mechanisms remain largely unclear. The gene discussed is SATB2; the disease is non-small cell lung carcinoma.